Infant Bacterial Therapeutics AB (publ)

Stockholm Stock Exchange IBT-B.ST

Infant Bacterial Therapeutics AB (publ) Operating Cash Flow for the year ending December 31, 2023: USD -9.99 M

Infant Bacterial Therapeutics AB (publ) Operating Cash Flow is USD -9.99 M for the year ending December 31, 2023, a -21.93% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Infant Bacterial Therapeutics AB (publ) Operating Cash Flow for the year ending December 31, 2022 was USD -8.19 M.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Stockholm Stock Exchange: IBT-B.ST

Infant Bacterial Therapeutics AB (publ)

CEO	Mr. Staffan Stromberg Ph.D.
IPO Date	March 29, 2016
Location	Sweden
Headquarters	Bryggargatan 10
Employees	9
Sector	Consumers Staples
Industries Baby & Childcare Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.

Key trends

Past 5 years